Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term study of intramuscular olanzapine depot in schizophrenia or schizoaffective disorder
2004-000986-37Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olanzapine in schizophrenia and schizoaffective disorder, sponsored by Eli Lilly and Company. Primary endpoints: Long-term safety of IM olanzapine depot, Long-term efficacy measured by PANSS and 1 more. Started Oct 2004; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2004-000986-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000986-37.